NCT00467506已完成2 期
Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 20
研究概览
简要总结
Phase II clinical trial assessing efficacy and toxicity of pretargeted radioimmunotherapy using anti-CEAxanti-DTPA bispecific antibody and di-DTPA-131I peptide in patients with reccurrence of medullary thyroid carcinoma (abnormal calcitonin level and biomarkers doubling time lower than 5 years)
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Factorial
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 -75 years
- •Karnofsky ≥ 70%
- •Histological diagnosis of medullary thyroid carcinoma
- •Calcitonin serum level Ê 100 pg/ml and Calcitonin or CEA doubling time £ 5 years
- •Normal liver and renal functions
- •Granulocytes ≥ 1500/mm3 and platelets ≥ 150 000/mm3
- •No immunization
- •Consent form signed
排除标准
- 未提供
研究者
研究点 (20)
Loading locations...
相似试验
已完成
1 期
Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin LymphomaNon-Hodgkin LymphomaNCT00302757University Hospital Tuebingen60
已完成
2 期
A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin LymphomasPrimary Non-Hodgkin-LymphomaRefractory Non-Hodgkin-LymphomaCD20+ Aggressive Non-Hodgkin's LymphomaNCT00521560Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH28
招募中
2 期
Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial MelanomaMelanoma MetastaticNCT06767306Melanoma Institute Australia129
撤回
2 期
Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic CancersMetastatic Colorectal CancerMetastatic Head and Neck CancerMetastatic Breast CancerNCT03323424Institut de Cancérologie de la Loire
进行中（未招募）
不适用
Multicenter phase I/II study of radioimmunotherapy with 90Y-ibritumomab tiuxetan in a nonmyeloablative conditioning regimen for allogeneic hematopoietic cell transplantation from HLA-identical donors in patients with advanced non-Hodgkin lymphomaEUCTR2005-002206-37-DEMedizinische Universitätsklinik II , Abteilung Hämatologie, Onkologie, Immunologie und Rheumatologie40